Premier Alternatives

AgomAb

Drug Discovery · Antwerp, Belgium · Founded 2017 · Privately Held (backing)

Developer of fibrotic disease treatments intended to preserve and restore organ function in fibrotic. AgomAb is based in Antwerp, Belgium and was founded in 2017. Its last known valuation is $416 million. It has raised $334 million across 1 recorded round; the latest was a $101 million Series C in Oct 2023.

Last price · $/share
—
Implied valuation
$415.6M
Total raised
$334.0M
Last round
Later Stage VC (Series C)
Oct 2023

AgomAb key facts

  • Developer of fibrotic disease treatments intended to preserve and restore organ function in fibrotic.
  • AgomAb’s last known valuation is $415.6M.
  • It has raised $334.0M across 1 recorded rounds; the latest was Later Stage VC (Series C) ($100.7M) in Oct 2023.
  • Notable investors include Fidelity Management & Research Company, Canaan Partners, The Invus Group, Cormorant Asset Management, EQT Life Sciences — 17 tracked in total.
  • Status: Privately Held (backing).
Free account
More of AgomAb with a free account
  • ·The complete investor list: 17 names
  • ·Watch AgomAb: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

AgomAb funding rounds

1 rounds
Oct 2023Later Stage VC (Series C)$100.7M▮
Full funding history →

AgomAb valuation

AgomAb's last known valuation is $416 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.

How much has AgomAb raised?

AgomAb has raised $334 million in total; 1 of its rounds is on record. The largest on record was a $101 million Series C in Oct 2023.

AgomAb investors

17 investors are on record for AgomAb, including Fidelity Management & Research Company, Canaan Partners, The Invus Group and Cormorant Asset Management. By type, the record holds 4 venture capital firms, 4 private equity firms and 1 hedge fund. The Series C in Oct 2023 drew 3 investors.

Comparable companies

Comparable drug discovery names by valuation on PrivateMarketView: CORXEL Pharmaceuticals ($475 million), Diagonal Therapeutics ($459 million) and Hemab Therapeutics Holdings ($387 million).

About AgomAb

Developer of fibrotic disease treatments intended to preserve and restore organ function in fibrotic. The company specializes in growth factor biology and offers treatment that simulates molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune, and degenerative diseases, enabling healthcare professionals to treat the patients more efficiently.

Industry
Drug Discovery
Sector
Healthcare
HQ
Antwerp, Belgium
Founded
2017
Employees
65
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.

Valuation on record
$415.6M

AgomAb’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.